ReviewInfectious diseases2016
Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance?
Review in Infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 83 citations in OpenAlex.
- Prevalence and Antimicrobial Resistance ofInfectious disease reports · 2026Article
- Co-Colonization by Multiple Multidrug-Resistant Organisms in a Long-Term Neurorehabilitation Setting: A Case Report.Microorganisms · 2026Article
- Impact of Lysine-Mediated C-Terminal Dimerization of Anoplin on Killing Kinetics and Antibiotic Interaction Profiles.Microorganisms · 2026Article
- Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns.Infectious disease reports · 2026Review
- Pattern of bacterial uropathogens and multidrug resistance in selected private laboratories, Ibb city, Yemen: a retrospective study.BMC infectious diseases · 2026Article
- Molecular Interplay of Brucellosis and Tuberculosis: Insights into Telomere Biology, Oxidative Stress, and Drug Resistance Mechanisms.Diseases (Basel, Switzerland) · 2026Review
- Disruption of Histidine Biosynthesis Impairs Outer Membrane Stability and Intracellular Survival ofMicroorganisms · 2026Article
- Paleopathology Meets Public Health: Deep-Time Syndemics and the Ecology of Emerging Infections.Pathogens (Basel, Switzerland) · 2026Review
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.Antimicrobial agents and chemotherapy · 2026Article
- Therapeutic milestones against multidrug resistant Acinetobacter baumannii: from legacy antibiotics to Zosurabalpin.Archives of microbiology · 2026Review
- Analysis of Macrolide Resistance inBiomedicines · 2026Article
- Development of a Prediction Model for Severe PediatricInfection and drug resistance · 2026Article
- Whole-genome sequencing identifies persistent transmission of a high-risk ST2Frontiers in microbiology · 2026Article
- Food-grade nanostructured delivery systems for oral administration of astaxanthin: Bioprocessing strategies and therapeutic applications.NPJ science of food · 2025Review
- Siderophore cephalosporins.EcoSal Plus · 2025Review
- Genomic Characterization of a Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025Article
- Decoding the regulatory networks ofFrontiers in cellular and infection microbiology · 2025Article
- Recent advances in host models in studying virulence factors and pathogenesis ofFrontiers in cellular and infection microbiology · 2025Review
- Efficacy of Cefiderocol Against Endophthalmitis Isolates.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance has been emerged as a major global health problem. In particular, gram-negative species pose a significant clinical challenge as bacteria develop or acquire more resistance mechanisms. Often, these bacteria possess multiple resistance mechanisms, thus nullifying most of the major classes of drugs. Novel approaches to this issue are urgently required. However, the challenges of developing new agents are immense. Introducing novel agents is fraught with hurdles, thus adapting known antibiotic classes by altering their chemical structure could be a way forward. A chemical addition to existing antibiotics known as a siderophore could be a solution to the gram-negative resistance issue. Siderophore molecules rely on the bacterial innate need for iron ions and thus can utilize a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.